General Investor Information EBR Systems, page-163

it's the typical frustrating low volume / easy manipulation zone, as is the case for most Australian biotechs.

The one other interesting point is the lack of attention or comments regarding the additional SOLVE-CRT data release on 2 September, so presumably released to the market on Monday 4 September. The fact it's been given a late-breaker presentation slot (with 108 patients) would surely point to the data being very good. And obviously adds to the data package for the FDA (the FDA has been largely insistent on randomised trials before approval).

but geez it would be good to get one green day, it's been a while